Tinengotinib

Tinengotinib
Clinical data
Other namesTT-00420
Identifiers
  • 4-[9-(2-chlorophenyl)-6-methyl-2,4,5,8,12-pentazatricyclo[8.4.0.03,7]tetradeca-1(14),3,6,8,10,12-hexaen-13-yl]morpholine
CAS Number
PubChem CID
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC20H19ClN6O
Molar mass394.86 g·mol−1
3D model (JSmol)
  • CC1=C2C(=NN1)NC3=CC(=NC=C3C(=N2)C4=CC=CC=C4Cl)N5CCOCC5
  • InChI=InChI=1S/C20H19ClN6O/c1-12-18-20(26-25-12)23-16-10-17(27-6-8-28-9-7-27)22-11-14(16)19(24-18)13-4-2-3-5-15(13)21/h2-5,10-11H,6-9H2,1H3,(H2,23,25,26)
  • Key:DQFCVOOFMXEPOC-UHFFFAOYSA-N


Tinengotinib is an investigational new drug that is being evaluated for the treatment of cancer.[1]

It is an multi-kinase inhibitor designed to target a range of kinases involved in cancer cell proliferation, angiogenesis, and immune response modulation. Specifically, it inhibits fibroblast growth factor receptors (FGFRs) 1-3, janus kinase (JAK) 1/2, vascular endothelial growth factor receptors (VEGFRs), and aurora kinases A/B.[2]

  1. ^ "Tinengotinib - TransThera Biosciences". AdisInsigh. Springer Nature Switzerland AG.
  2. ^ Peng P, Qiang X, Li G, Li L, Ni S, Yu Q, et al. (February 2023). "Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer". Molecular Cancer Therapeutics. 22 (2): 205–214. doi:10.1158/1535-7163.MCT-22-0012. PMC 9890131.